Regulation of NUCB2/nesfatin-1 production in rat's stomach and adipose tissue is dependent on age, testosterone levels and lactating status

Molecular and Cellular Endocrinology

Volumn 411, Issue , 2015, Pages 105-112

  Senin, Lucia L ^a,b,d   Al Massadi, Omar ^b,c,d   Barja Fernandez, Silvia ^a,b,c,d   Folgueira, Cintia ^a,b,c,d   Castelao, Cecilia ^a,b,d   Tovar, Sulay A ^b,c,d   Leis, Rosaura ^c,d   Lago, Francisca ^a,d   Baltar, Javier ^a   Baamonde, Ivan ^a   Dieguez, Carlos ^b,c,d   Casanueva, Felipe F ^b,c,d   Seoane, Luisa M ^a,b,d  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^d Santiago University Clinical Hospital   (Spain)

Author keywords

Adipose tissue; Breastfeeding and puberty; NUCB2 nesfatin 1; Sex; Stomach

Indexed keywords

MESSENGER RNA; NESFATIN 1; NUCLEOBINDIN 2; REGULATOR PROTEIN; TESTOSTERONE; UNCLASSIFIED DRUG; CALCIUM BINDING PROTEIN; DNA BINDING PROTEIN; NERVE PROTEIN; NUCLEOBINDIN;

ADIPOSE TISSUE; ADULT; AGE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST FEEDING; CONTROLLED STUDY; DEVELOPMENTAL STAGE; FEMALE; GENE EXPRESSION; LACTATION; MALE; MATURATION; NESFATIN 1 GENE; NONHUMAN; NUCB2 GENE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN SECRETION; PUBERTY; RAT; REGULATOR GENE; REGULATORY MECHANISM; STOMACH MUCOSA; TESTOSTERONE BLOOD LEVEL; WEANING; ANIMAL; BLOOD; ENERGY METABOLISM; METABOLISM; SPRAGUE DAWLEY RAT; STOMACH;

ADIPOSE TISSUE; AGE FACTORS; ANIMALS; CALCIUM-BINDING PROTEINS; DNA-BINDING PROTEINS; ENERGY METABOLISM; FEMALE; LACTATION; MALE; NERVE TISSUE PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; STOMACH; TESTOSTERONE;

EID: 84930506882     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2015.04.016     Document Type: Article

References (36)

1. Al-Massadi O., Crujeiras A.B., et al. Age, sex, and lactating status regulate ghrelin secretion and GOAT mRNA levels from isolated rat stomach. Am. J. Physiol. Endocrinol. Metab 2010, 299(3):E341-E350.
2. Aydin S. The presence of the peptides apelin, ghrelin and nesfatin-1 in the human breast milk, and the lowering of their levels in patients with gestational diabetes mellitus. Peptides 2010, 31(12):2236-2240.
3. Bohler H., Mokshagundam S., et al. Adipose tissue and reproduction in women. Fertil. Steril 2010, 94(3):795-825.
4. Brailoiu G.C., Dun S.L., et al. Nesfatin-1: distribution and interaction with a G protein-coupled receptor in the rat brain. Endocrinology 2007, 148(10):5088-5094.
5. Carro E., Pinilla L., et al. Influence of endogenous leptin tone on the estrous cycle and luteinizing hormone pulsatility in female rats. Neuroendocrinology 1997, 66(6):375-377.
6. Feijoo-Bandin S., Rodriguez-Penas D., et al. Nesfatin-1 in human and murine cardiomyocytes: synthesis, secretion, and mobilization of GLUT-4. Endocrinology 2013, 154(12):4757-4767.
7. Foo K.S., Brismar H., et al. Distribution and neuropeptide coexistence of nucleobindin-2 mRNA/nesfatin-like immunoreactivity in the rat CNS. Neuroscience 2008, 156(3):563-579.
8. Fort P., Salvert D., et al. The satiety molecule nesfatin-1 is co-expressed with melanin concentrating hormone in tuberal hypothalamic neurons of the rat. Neuroscience 2008, 155(1):174-181.
9. Garcia-Galiano D., Navarro V.M., et al. The anorexigenic neuropeptide, nesfatin-1, is indispensable for normal puberty onset in the female rat. J. Neurosci 2010, 30(23):7783-7792.
10. Garcia-Galiano D., Pineda R., et al. Cellular distribution, regulated expression, and functional role of the anorexigenic peptide, NUCB2/nesfatin-1, in the testis. Endocrinology 2012, 153(4):1959-1971.
11. Goebel M., Stengel A., et al. Nesfatin-1 immunoreactivity in rat brain and spinal cord autonomic nuclei. Neurosci. Lett 2009, 452(3):241-246.
12. Goebel M., Stengel A., et al. Lipopolysaccharide increases plasma levels of corticotropin-releasing hormone in rats. Neuroendocrinology 2011, 93(3):165-173.
13. Hansson C., Alvarez-Crespo M., et al. Influence of ghrelin on the central serotonergic signaling system in mice. Neuropharmacology 2014, 79:498-505.
14. Inhoff T., Monnikes H., et al. Desacyl ghrelin inhibits the orexigenic effect of peripherally injected ghrelin in rats. Peptides 2008, 29(12):2159-2168.
15. Kohno D., Nakata M., et al. Nesfatin-1 neurons in paraventricular and supraoptic nuclei of the rat hypothalamus coexpress oxytocin and vasopressin and are activated by refeeding. Endocrinology 2008, 149(3):1295-1301.
16. Li J.B., Nishida M., et al. Effects of aging on the plasma levels of nesfatin-1 and adiponectin. Biomed. Rep 2014, 2(1):152-156.
17. Li Q.C., Wang H.Y., et al. Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrient-related fluctuation of nesfatin-1 level in normal humans. Regul. Pept 2010, 159(1-3):72-77.
18. Li Z., Xu G., et al. mTOR-dependent modulation of gastric nesfatin-1/NUCB2. Cell. Physiol. Biochem 2012, 29(3-4):493-500.
19. Maejima Y., Sedbazar U., et al. Nesfatin-1-regulated oxytocinergic signaling in the paraventricular nucleus causes anorexia through a leptin-independent melanocortin pathway. Cell Metab 2009, 10(5):355-365.
20. Mohan H., Unniappan S. Ontogenic pattern of nucleobindin-2/nesfatin-1 expression in the gastroenteropancreatic tissues and serum of Sprague Dawley rats. Regul. Pept 2012, 175(1-3):61-69.
21. Noetzel S., Stengel A., et al. CCK-8S activates c-Fos in a dose-dependent manner in nesfatin-1 immunoreactive neurons in the paraventricular nucleus of the hypothalamus and in the nucleus of the solitary tract of the brainstem. Regul. Pept 2009, 157(1-3):84-91.
22. Oh I.S., Shimizu H., et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006, 443(7112):709-712.
23. Osaki A., Shimizu H., et al. Enhanced expression of nesfatin/nucleobindin-2 in white adipose tissue of ventromedial hypothalamus-lesioned rats. Neurosci. Lett 2012, 521(1):46-51.
24. Pan W., Hsuchou H., et al. Nesfatin-1 crosses the blood-brain barrier without saturation. Peptides 2007, 28(11):2223-2228.
25. Ramanjaneya M., Chen J., et al. Identification of nesfatin-1 in human and murine adipose tissue: a novel depot-specific adipokine with increased levels in obesity. Endocrinology 2010, 151(7):3169-3180.
26. Riva M., Nitert M.D., et al. Nesfatin-1 stimulates glucagon and insulin secretion and beta cell NUCB2 is reduced in human type 2 diabetic subjects. Cell Tissue Res 2011, 346(3):393-405.
27. Senin L.L., Al-Massadi O., et al. The gastric CB1 receptor modulates ghrelin production through the mTOR pathway to regulate food intake. PLoS ONE 2013, 8(11):e80339.
28. Seoane L.M., Al-Massadi O., et al. Sensory stimulus directly acting at the central nervous system regulates gastric ghrelin secrection. An ex vivo organ cultura. Endocrinology 2007, 148(8):3998-4006.
29. Shimizu H., Oh I.S., et al. Peripheral administration of nesfatin-1 reduces food intake in mice: the leptin-independent mechanism. Endocrinology 2009, 150(2):662-671.
30. Stengel A., Taché Y. Role of NUCB2/Nesfatin-1 in the hypothalamic control of energy homeostasis. Horm. Metab. Res 2013, 45(13):975-979.
31. Stengel A., Goebel M., et al. Identification and characterization of nesfatin-1 immunoreactivity in endocrine cell types of the rat gastric oxyntic mucosa. Endocrinology 2009, 150(1):232-238.
32. Stengel A., Mori M., et al. The role of nesfatin-1 in the regulation of food intake and body weight: recent developments and future endeavors. Obes. Rev 2013, 14(11):859-870.
33. Su Y., Zhang J., et al. The novel function of nesfatin-1: anti-hyperglycemia. Biochem. Biophys. Res. Commun 2010, 391(1):1039-1042.
34. Tagaya Y., Osaki A., et al. Secreted nucleobindin-2 inhibits 3T3-L1 adipocyte differentiation. Protein Pept. Lett 2012, 19(9):997-1004.
35. Tsuchiya T., Shimizu H., et al. Fasting concentrations of nesfatin-1 are negatively correlated with body mass index in non-obese males. Clin. Endocrinol. (Oxf) 2010, 73(4):484-490.
36. Zhang Z., Li L., et al. Increased plasma levels of nesfatin-1 in patients with newly diagnosed type 2 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes 2012, 120(2):91-95.